Comparison in patients with type 2 diabetes of fibric acid versus HMG-CoA reductase inhibitor treatment of combined dyslipidemia

被引：0
|
作者：
McLaughlin, TL
Abbasi, F
Lamendola, CA
Leary, E
Reaven, GM
机构：
来源：
DIABETES | 2002年 / 51卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2036
引用
收藏
页码：A495 / A496
页数：2
相关论文
共 50 条
  • [21] HMG-CoA reductase inhibitors prevent bone loss in patients with Type 2 diabetes mellitus
    Nakashima, A
    Nakashima, R
    Ito, T
    Masaki, T
    Yorioka, N
    DIABETIC MEDICINE, 2004, 21 (09) : 1020 - 1024
  • [22] Effects of simvastatin, an HMG-CoA reductase inhibitor, in patients with hypertriglyceridemia
    Isaacsohn, J
    Hunninghake, D
    Schrott, H
    Dujovne, CA
    Knopp, R
    Weiss, SR
    Bays, H
    Crouse, JR
    Davidson, MH
    Keilson, LM
    McKenney, J
    Korenman, SG
    Dobs, AS
    Stein, E
    Krauss, RM
    Maccubbin, D
    Cho, M
    Plotkin, DJ
    Mitchel, YB
    CLINICAL CARDIOLOGY, 2003, 26 (01) : 18 - 24
  • [23] The Effects of Pemafibrate in Japanese Patients with Type 2 Diabetes Receiving HMG-CoA Reductase Inhibitors
    Kusunoki, Masataka
    Sakazaki, Takahiko
    Tsutsumi, Kazuhiko
    Miyata, Tetsuro
    Oshida, Yoshiharu
    ENDOCRINE METABOLIC & IMMUNE DISORDERS-DRUG TARGETS, 2021, 21 (05) : 919 - 924
  • [24] Periodontal infection and dyslipidemia in type 2 diabetics: Association with increased HMG-CoA reductase expression
    Nishimura, F.
    Taniguchi, A.
    Yamaguchi-Morimoto, M.
    Soga, Y.
    Iwamoto, Y.
    Kokeguchi, S.
    Kuroe, A.
    Fukushima, M.
    Nakai, Y.
    Seino, Y.
    HORMONE AND METABOLIC RESEARCH, 2006, 38 (08) : 530 - 535
  • [25] Risk of Diabetes in Patients Treated with HMG-CoA Reductase Inhibitors
    Wang, Hye Jin
    Cho, Yongin
    Choe, Eun Yeong
    Seo, Ji Won
    Lee, Yongho
    Yun, Yu Jung
    Kim, Gyuri
    Park, Sehee
    Bae, Jaehyun
    Ahn, Chul Woo
    Cha, Bong Soo
    Lee, Hyun Chul
    Kang, Eun Seok
    DIABETES, 2014, 63 : A367 - A367
  • [26] Risk of diabetes in patients treated with HMG-CoA reductase inhibitors
    Cho, Yongin
    Choe, EunYeong
    Lee, Yong-ho
    Seo, Ji Won
    Choi, Younjeong
    Yun, Yujung
    Wang, Hye Jin
    Ahn, Chul Woo
    Cha, Bong Soo
    Lee, Hyun Chul
    Kang, Eun Seok
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2015, 64 (04): : 482 - 488
  • [27] Atorvastatin - Novel inhibitor of HMG CoA reductase for the treatment of atherosclerosis and dyslipidemia
    Oganov, RG
    Akhmedzhanov, NM
    KARDIOLOGIYA, 2000, 40 (07) : 62 - 67
  • [28] A comparison of continuous combined hormone replacement therapy, HMG-CoA reductase inhibitor and combined treatment for the management of hypercholesterolemia in postmenopausal women
    Ozsener, S
    Sendag, F
    Koc, T
    Terek, MC
    Oztekin, K
    Bilgin, O
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2001, 27 (06) : 353 - 358
  • [29] FOCUS ON SIMVASTATIN - A POTENT HMG-COA REDUCTASE INHIBITOR FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA
    QUERCIA, RA
    HOSPITAL FORMULARY, 1989, 24 (10): : 559 - &
  • [30] HMG-CoA reductase inhibitors prevent bone loss in patients with type 2 diabetes mellitus.
    Nakashima, A
    Nakashima, R
    Masaki, T
    Harada, S
    Yorioka, N
    DIABETES, 2003, 52 : A128 - A128
12345